Autonomix Medical to Present Transvascular Neural Sensing at CRT 2026 Competition
Autonomix Medical’s transvascular precision-guided neural sensing tech has been selected for oral presentation in the Best Innovation Competition at CRT 2026, with CEO Brad Hauser presenting on March 9. The recognition underscores scientific validation of its catheter-based microchip array, potentially accelerating clinical adoption and investor confidence.
1. Selection for CRT 2026 Competition
Autonomix Medical’s presentation, “Illuminating The Nervous System With Transvascular Precision-guided Technology,” has been chosen for oral delivery in the Best Innovation Competition at CRT 2026. CEO Brad Hauser will deliver the eight-minute talk on March 9 from 4:19 to 4:27 PM ET in the International Ballroom – West.
2. Significance of Competition
The CRT Best Innovation Competition spotlights top abstracts based on scientific merit, technical differentiation and clinical relevance. Selection for oral presentation reflects independent validation of Autonomix’s catheter-based microchip sensing array and may bolster the company’s clinical development roadmap and investor appeal.
3. Technology and Clinical Potential
Autonomix’s first-in-class platform uses a catheter-based microchip array to detect and differentiate peripheral neural signals with enhanced sensitivity, aiming to enable the first transvascular diagnosis and treatment of diseases such as pancreatic cancer pain. The system’s broad applicability spans cardiology, hypertension and chronic pain management, pending U.S. regulatory clearance.